Get the Stockscreener App
21.81
8.35%
1.68
Pre-market:
21.76
-0.05
-0.23%
Rigel Pharmaceuticals stock is traded at $21.81, with a volume of 349.57K.
It is up +8.35% in the last 24 hours and up +27.62% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$20.13
Open:
$20.35
24h Volume:
349.57K
Relative Volume:
1.36
Market Cap:
$384.18M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-155.79
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+30.68%
1M Performance:
+27.62%
6M Performance:
+125.78%
1Y Performance:
+60.37%
1-Day Range:
$19.58
$21.83
1-Week Range:
$17.10
$21.83
52-Week Range:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
21.81 | 384.18M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
JW Pharmaceutical gains approval for immune thrombocytopenia treatment TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Long Term Trading Analysis for (RIGL) - Stock Traders Daily
KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel PharmaceuticalsCHOSUNBIZ - 조선비즈
Assenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Barclays PLC Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Short Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1% - MarketBeat
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Rigel (RIGL) Upgraded to Buy: Here's Why - MSN
Equities Analysts Set Expectations for RIGL Q4 Earnings - MarketBeat
Rigel Pharmaceuticals Seeks for Acquisitions -January 16, 2025 at 11:15 am EST - Marketscreener.com
Cantor Fitzgerald Has Positive View of RIGL FY2024 Earnings - MarketBeat
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rigel forecasts revenue growth in 2025, reports Q4 sales - Investing.com India
RIGLRigel Pharmaceuticals Inc. (New) Latest Stock News & Market Updates - StockTitan
Rigel Pharmaceuticals sets 2025 sales outlook above estimates - MSN
Rigel forecasts revenue growth in 2025, reports Q4 sales By Investing.com - Investing.com South Africa
Rigel Provides Business Update and 2025 Outlook - PR Newswire
Rigel Pharma Revenue Soars as TAVALISSE Hits $100M Sales Milestone, Sets Ambitious 2025 Targets - StockTitan
(RIGL) Technical Data - Stock Traders Daily
Rigel announces R289 granted Orphan Drug designation by FDA for MDS - TipRanks
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289 - MarketWatch
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire
Rigel's MDS Drug R289 Receives FDA Orphan Drug Status, Boosting Market Exclusivity Potential - StockTitan
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Confe - GuruFocus.com
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
Jane Street Group LLC Lowers Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Malaysian Reserve
Brokerages Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $36.20 - MarketBeat
Rigel Pharma expects to complete workforce reduction by Dec 15 - Reuters
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents (NASDAQ:RIGL) - Seeking Alpha
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St
Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
(RIGL) Trading Signals - Stock Traders Daily
Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St
Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail
Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve
Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat
Rigel Pharmaceuticals announces initial data from Phase 1b study of R289 - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Rigel's R289 Shows 40% Response Rate in Blood Cancer Trial, Earns FDA Fast Track Status - StockTitan
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):